Evolving heart

By Elie Dolgin Evolving heart In 1948, 5,209 residents of a medium-sized New England town signed up for what would become the longest-running, systematic medical study in the world. The Framingham Heart Study, as it was called, was the first to show that smoking, obesity, and high cholesterol all increased people’s chances of developing heart disease. Six decades on, it’s also the first multigenerational human study to reveal that

Written byElie Dolgin
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In 1948, 5,209 residents of a medium-sized New England town signed up for what would become the longest-running, systematic medical study in the world. The Framingham Heart Study, as it was called, was the first to show that smoking, obesity, and high cholesterol all increased people’s chances of developing heart disease. Six decades on, it’s also the first multigenerational human study to reveal that some of these same traits are actively undergoing natural selection.

The news should come as a surprise to many physicians. Ever since Charles Darwin, a prevailing attitude among medical practitioners has been that evolution does not operate in humans because modern medicine and culture have greatly leveled the playing field by homogenizing survival rates. The same sentiment has also been echoed by some leading evolutionary biologists, most famously the late Stephen Jay Gould.

Re-engineering humans

Ancient iceman has no modern kin

Ancient organism, modern immunity

Not ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies